Cancer: A mutation that breaks gene interplay in 3-D
Inside cells DNA is tightly wrapped around proteins and packed in a complex, 3-D structure called chromatin. Chromatin not only protects genetic material from damage, but also organizes the entire genome by regulating the expression of genes in three dimensions, unwinding them for presentation to the cell's gene-expression machinery and then winding them back in.
Inside the 3-D chromatin structure, there are specific regions called topologically associating domains (TADs). These contain DNA sequences (thousands to millions of DNA bases) that physically interact with each other, suggesting that the genes in these domains may be working together. Discovered in 2012, the functions of TADs are not yet fully understood, but it is known that disrupting TADs disrupts gene regulation, and this can be a mechanism that cancer cells use to alter gene expression.
Now, scientists led by Elisa Oricchio at EPFL, in collaboration with Giovanni Ciriello at UNIL, have discovered that a mutation of a particular gene leads to modifying interactions within TADs. The gene is called EZH2, and is normally involved in the repression of gene transcription—the first step in gene expression. In fact, EZH2 mutations play key roles in the initiation of tumors and can be used as markers for diagnosing several types of cancer.
The scientists studied what is known as a gain-of-function mutation of EZH2. These types of mutations exacerbate the gene's function and help tumor cells to grow. Here, the researchers found that EZH2 does not act randomly across the genome, but preferentially within specific TADs.
Mutated EZH2 shuts down entire domains, turning off genes that normally suppress tumors. In their study, the loss of multiple genes synergistically accelerated the development of the tumors. And when the researchers inhibited mutated EZH2 with a drug, all the functions were restored.
The study is the first to show that mutated EZH2 affects not individual genes but entire chromatin domains, changing the interactions and expression of tumor-suppressive genes contained in those domains. "The study highlights the importance of considering the 3-D organization of the genome in the nucleus to better understand how mutations in cancer cells exploit this organization to support tumor growth," says Elisa Oricchio. "Pharmacological inhibitors that block EZH2 oncogenic activity are currently in clinical trials, and this study provides further insight on their therapeutic potential."
The study is published in Nature Genetics.
More information: Maria C. Donaldson-Collier et al. EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains, Nature Genetics (2019). DOI: 10.1038/s41588-018-0338-y
Journal information: Nature Genetics
Provided by Ecole Polytechnique Federale de Lausanne